Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies is the fifth volume in the series Cancer Treatment, and Research' devoted to pediatric oncology. Like its immediate predecessor, *Hodgkin's Disease in Children: Controversies and Current* *Practice* , this volume also deals with the current state of affairs: where do researchers differ in opinions or firmly held beliefs? What does the future hold for research or for the patients who have benefited from research and are now cured? etc. The first part deals with preclinical and clinical issues that relate to the disease and the second part deals with the results of recent trials and in some cases ongoing trials. It could be argued that section B Pharmacology, Section D Radiotherapy and Section E Surgery of part one belong to part two; however in these sections we have tried to focus on one discipline and in part two, we have tried to focus on the results of multidisciplinary trials. A third part includes a few critiques and editorial comments. This volume was prepared and planned for both basic and clinical oncologists. It is hoped that the basic scientists will gain some insight into the problems of their clinical colleagues and that the clinicians will be willing to read to the more basic articles. It is not a text for students (or for that matter physicians) who want all things to be laid out in black and white'. But it is a text for those students who want to know how vibrant this field of research is and are willing to stand in awe of how much research needs to be done.

Klappentext

Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies is the fifth volume in the series Cancer Treatment, and Research' devoted to pediatric oncology. Like its immediate predecessor, Hodgkin's Disease in Children: Controversies and Current Practice, this volume also deals with the current state of affairs: where do researchers differ in opinions or firmly held beliefs? What does the future hold for research or for the patients who have benefited from research and are now cured? etc. The first part deals with preclinical and clinical issues that relate to the disease and the second part deals with the results of recent trials and in some cases ongoing trials. It could be argued that section B Pharmacology, Section D Radiotherapy and Section E Surgery of part one belong to part two; however in these sections we have tried to focus on one discipline and in part two, we have tried to focus on the results of multidisciplinary trials. A third part includes a few critiques and editorial comments. This volume was prepared and planned for both basic and clinical oncologists. It is hoped that the basic scientists will gain some insight into the problems of their clinical colleagues and that the clinicians will be willing to read to the more basic articles. It is not a text for students (or for that matter physicians) who want all things to be laid out in black and white'. But it is a text for those students who want to know how vibrant this field of research is and are willing to stand in awe of how much research needs to be done.

Inhalt
I. Selected Topics: A. Introduction.- 1. Osteosarcoma at the end of the 20th century/Tumor biology.- B. General.- 2. Retroviruses and oncogenes associated with osteosarcomas.- 3. In vivo 31-phosphorus nuclear magnetic resonanc spectroscpy of osteosarcoma.- 4. Perioperative blood transfusions and survival in osteosarcoma.- 5. Adjuvant interferon treatment in human osteosarcoma.- 6. Difference of osteosarcoma between Southwest England and the Kanto area of Japan in relation to age, sex and localization.- 7. Psychological effects of amputation in osteosarcoma.- 8. Late effects of therapy in survivors of childhood and adolescent osteosarcoma.- C. Pharmacology.- 9. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.- 10. Doxorubicin: Role in the treatment of osteosarcoma.- 11. Pediatric osteosarcoma: Treatment of the primary tumor with intraarterial cis-Diamminedichloroplatinum-II (CDP) Advantages, disadvantages and controversial issues.- 12. Intraarterial chemotherapy for osteosarcoma: Does the result really justify the effort.- 13. Thermal chemosensitization of DDP in normal and resistant cells.- 14. Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma.- D. Pathology.- 15. Pathological diagnosis of osteosarcoma: The validity of the subclassification and some new diagnostic approaches using immunohistochemistry.- 16. Histologic subclassification of osteosarcoma: Differential diagnostic problems and immunohistochemical aspects.- 17. Small cell osteosarcoma.- 18. Current status of DNA cytometry in osteosarcoma.- 19. Osteosarcomatosis and metastatic osteosarcoma.- E. Radiotherapy.- 20. Experience of the EORTC Radiotherapy/Chemotherapy Group and in osteosarcoma trials.- 21. Intraoperative radiation therapy for osteosarcoma.- F. Surgery.- 22. Surgery of osteosarcoma of the extremities: Indications and Complications in the recent experience at the Instituto Ortopedico Rizzoli.- 23. Limb sparing for skeletally immature patients with osteosarcoma: The expandable Prosthesis.- 24. A modular endoprosthetic system, non-invasively extendable, for young patients with osteosarcoma.- 25. A critique of techniques for reconstruction after internal hemipelvectomy for osteosarcoma.- 26. Diffusion of methotrexate from surgical acrylic cement.- 27. Hyperthermic isolated prefusion using Cisplatin for the treatment of the extremities.- 28. Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics and toxicity of Cisplatin.- 29. Effect of isolated limb prefusion with Cisplatin (CDDP) on canine osteosarcoma.- 30. Salvage surgery for childhood osteosarcoma.- II. CO-Operative Groups And Institutional Reports: A. Co-operative Groups.- 31. The Multiinstitutional Osteosarcoma Study: An update..- 32. Treatment of osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group (COSS).- 33. The European Osteosarcoma Intergroup (E.O.I.) Studies 19801991.- 34. The Children's Cancer Study Group (CCSG) Studies.- 35. An update of Scandinavian studies of osteosarcoma.- B. Institutional Reports.- 36. Neoadjuvant chemotherapy for non metastatic osteosarcoma of the extremities: The recent experience at the Rizzoli Institute.- 37. Osteosarcoma of the extremities: Chemotherapy experience at Memorial Sloan-Kettering.- 38. Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.- 39. A monocentric therapy study: An approach to optimize the results of thetreatment of osteosarcoma by protocols based upon HD MTX, associated with systematic conservative surgery.- 40. The Mayo Clinic studies.- 41. Neoadjuvant Chemotherapy for Patients with osteosarcoma: University of Flordia studies.- 42. Chemotherapy in osteogenic sarcoma: The experience of the Pediatric Department of the Gustave Roussy Institute.- 43. Results of therapy in osteosarcoma: Experience in children hospitals in Buenos Aires.- 44. Osteosarcoma: Experience with the Rosen T10 protocol at RCH, Melbourne.- 45. Osteosarcoma of the limb: An institutional report of 10 years experience with neoadjuvant chemotherapy and delayed surgery.- 46. Osteosarcoma: Experience of the Tata Memorial Hospital, Bombay, India.- 47. Update of osteosarcoma in Ramathibodi, Thailand.- III. Summaries, Critiques and Editorial Comments.- 48. Commentary on pathology.- 49. Is there a rational role for radiotherapy in the treatment of osteosarcoma? A radiotherapist's point of view.- 50. Commentary on the use of presurgical chemotherapy.- 51. Critique on the use of presurgical chemotherapy.